Winston Francois builds product marketing that clears MLR on the first pass instead of the fourth, and that gives HCPs and patients messaging built from the same approved label instead of two teams improvising separately. We embed as your fractional product marketing team, not a deck-and-disappear agency.
The Problem
Pre-Launch Messaging Has to Educate Without Promoting a Product That Does Not Exist Yet
Before approval, anything that looks like a product claim is off-label promotion, so pre-launch marketing has to live entirely in disease-state and unmet-need territory. Most product marketing teams either play it too safe and build zero commercial momentum, or drift into implied product claims that regulatory has to kill days before a conference. The label is not final until it is final, and a messaging platform built around an assumed indication gets rewritten the week the label actually clears.
MLR Turns Every Asset Into a Multi-Week Negotiation
A one-page leave-behind or a single email can take three to six weeks to clear Medical, Legal, and Regulatory review, especially when the reviewers see the same claim phrased three different ways because nobody built a shared claims library. Marketing calendars get built around ideal timelines and then quietly rewritten around whatever actually cleared review that week. The cost is not just delay – it is a launch narrative that arrives in fragments instead of as one coherent story.
HCP and Patient Messaging Have to Trace to the Same Label and Rarely Do
HCP-facing materials talk mechanism, efficacy data, and dosing; patient-facing materials talk quality of life and what to expect. Both have to be traceable back to the same approved label, but when they are built by different teams on different timelines, the claims drift apart and MLR ends up reviewing two inconsistent stories instead of one architecture with two audience layers. Fixing the drift after the fact costs more review cycles than building it right the first time.
Standard of Care and Off-Label Use Are the Real Competitors, and You Cannot Say So Directly
The product rarely competes against another branded drug in a head-to-head trial – it competes against a generic standard of care, a watch-and-wait protocol, or an off-label use of something else entirely. Fair balance rules and the absence of head-to-head data mean marketing cannot make a direct comparative claim, so positioning has to win the argument without ever naming the alternative outright. Most product marketing teams either avoid the comparison entirely, which wastes the strongest argument in the room, or get too close to the line and trigger a compliance rewrite.
Medical Affairs, Commercial, and Regulatory Are Building Three Different Launch Stories
Medical Affairs owns the scientific narrative for KOLs and advisory boards, Commercial owns the promotional story for the field force, and Regulatory owns the label and what can legally be claimed – and there is often no single document that reconciles the three. Sales reps hear one thing from an MSL slide deck and a different emphasis from the launch playbook, and by the time a KOL repeats the wrong framing at a conference, the inconsistency is already public.
Sales Enablement Materials Lag the Approved Claims by Months
Field reps need materials the day the label clears, not the quarter after, but sales enablement content usually sits behind the same MLR queue as everything else with no priority lane. Reps without approved materials either go quiet on the product's real advantages or improvise talking points that were never reviewed, and an unreviewed rep comment is exactly the kind of exposure a compliance audit exists to catch.
How We Help
We start with a two-week audit of your actual messaging architecture and MLR history, not the launch plan in the slide deck.
From that audit we build a claims library: every approved claim from the label, broken into modular building blocks, each one pre-mapped to the label language that supports it.
On top of the claims library we build two messaging architectures – one for HCPs, one for patients – that share the same underlying claim set but speak to each audience's actual decision. The HCP architecture leads with mechanism, data, and dosing context.
For competitive positioning, we build the argument around the unmet need the standard of care leaves unaddressed, not a head-to-head comparison the data does not support.
We run launch coordination as one joint working session between Commercial, Medical Affairs, and Regulatory, not three separate documents that get reconciled two weeks before launch.
Sales enablement gets built from the claims library from day one, submitted to MLR in parallel with the core launch assets instead of behind them, so reps have approved materials the week the label clears instead of the quarter after.
What we deliver
- Messaging and MLR-history audit with average cycle time by asset type
- Modular claims library mapped to approved label language
- HCP-facing messaging architecture built from the shared claims library
- Patient-facing messaging architecture built from the same claims library
- Competitive positioning framework built around unmet need, not head-to-head comparison
- Joint launch narrative reconciling Medical Affairs, Commercial, and Regulatory into one story
- Sales enablement materials submitted to MLR in parallel with core launch assets
Most biotech product marketing teams treat MLR as an obstacle to route around. The teams that actually launch on time treat MLR as the audience the message has to be built for from the first draft.
Our Methodology
We run in 90-day sprints because that is long enough to fix the actual bottleneck and short enough that we are never optimizing around an assumption that changes before launch. Days 1-15 are the audit: MLR cycle history, existing claims inventory, and where the HCP and patient stories have already drifted apart. Days 16-45 are the build: the claims library, the two messaging architectures, and the competitive positioning framework, all drafted with Medical and Regulatory in the room, not after them.
Days 46-75 push assets through MLR using the new library and track exactly how much faster they clear compared to the baseline from the audit. Days 76-90 are launch coordination and sales enablement handoff, so the field force has approved materials in hand rather than a promise that materials are coming.
This is different from a typical launch agency engagement in one specific way: we do not hand you a messaging deck and move to the next client. We sit in the MLR queue with you, we know why a claim got kicked back, and we fix the underlying architecture instead of resubmitting the same language with different formatting.
How We Work
The first 30 days are diagnostic. We pull your MLR submission history, sit in on review meetings if Legal and Regulatory allow it, and come back with a claims library and a cycle-time baseline instead of a generic launch framework.
Days 31-60 are build and submission. We draft the HCP and patient messaging architectures and the sales enablement core from the claims library, submit them into your actual MLR queue, and adjust based on real reviewer feedback instead of a hypothetical one.
By day 90 you have a claims library your team can build new assets from without starting the claim-defense argument over every time, plus a track record of faster MLR cycles you can point to. From there we typically stay on fractional through launch and into the first post-launch messaging refresh, cadence set by your review calendar – weekly during active submission periods, biweekly once the library is doing its job.
If your biotech or pharma company needs product marketing that survives MLR instead of fighting it, we should talk.
- Faster MLR cycle times on assets built from the shared claims library
- HCP and patient messaging that trace to the same approved label without drift
- Competitive positioning that clears review because it never makes an unsupported comparison
- One joint launch narrative instead of three department-specific stories
- Sales enablement materials ready the week the label clears, not the quarter after
- Fewer resubmissions from claims that were defensible but poorly mapped to label language
If your biotech & pharma company needs product marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How do you shorten MLR review time without cutting corners on compliance?
We do not touch the review standard – Medical, Legal, and Regulatory still evaluate every asset on its merits. What changes is that assets get built from a pre-mapped claims library, so reviewers are checking whether a claim already established as defensible was used correctly, rather than evaluating a brand-new argument from scratch every time.
Can you build patient-facing messaging before the drug is approved?
Pre-approval, we build disease-state and unmet-need messaging that never implies a product claim, which is what regulatory guidelines actually allow. The product-specific patient architecture gets built once the label locks, using the same claims library as the HCP materials, so both are ready to move together instead of the patient side trailing by months.
How do you position against standard of care without making a comparative claim?
We build the argument around the gap the standard of care leaves open – tolerability, monitoring burden, or inadequate control – and let the label's own data speak to that gap, without ever naming the alternative directly. That approach clears review because it never asserts a head-to-head result the trial data does not support, and it is usually a stronger argument than a direct comparison would be anyway.
How do you get Medical Affairs, Commercial, and Regulatory to agree on one launch story?
We run a joint working session where all three groups build the messaging house together instead of each drafting a separate version and reconciling it later. Everyone leaves with the same claims library and the same narrative, which means the KOL deck, the rep talking points, and the regulatory-approved label language actually say the same thing.
What does a product marketing engagement cost for a biotech or pharma company?
Engagements are scoped fractional, typically in the range of $15K-$35K per month depending on how many assets are moving through MLR concurrently and how much of the claims library already exists. That covers an embedded team working your actual review queue, not a fixed set of deliverables handed off and forgotten.
How soon before launch should we bring in a fractional product marketing team?
Ideally 4 to 6 months before label lock, so the claims library and both messaging architectures are built and already moving through MLR before launch week arrives. Coming in later is still useful, but it usually means compressing the claims-library work into fewer review cycles, which is exactly the bottleneck that causes fragmented launches in the first place.
Is this a fit for a company that has never launched a product before?
Yes, and in some ways it is easier than fixing a messaging architecture that already has a year of inconsistent, MLR-rejected drafts behind it. First-time launch teams get the claims library built correctly from the start instead of untangling HCP and patient messaging that already drifted apart under deadline pressure.
